COVID-19 Vaccine, Adjuvanted (Novavax)

Achieved total revenue of $415 million in the second quarter of 2024 and ended the period with $1.1 billion in Cash Filed with the U.S. FDA and EMA for authorization of updated 2024-2025 formula COVID-19 vaccine Received $570 million in upfront payment and equity investment from Sanofi; progressed operationalization of Sanofi partnership Phase 3 trial initiation for COVID-19-Influenza Combination and stand-alone influenza vaccines planned for Q4 2024; data expected by mid-2025 Company to host conference call today at 8:30 a.m. ET GAITHERSBURG, Md., Aug. 8, 2024 /PRNewswire/ -- Novavax, Inc. (Nasdaq: NVAX), a global company advancing protein-based vaccines with its Matrix-M™ adjuvant, today announced its financial results and operational highlights for the second quarter ended June 30, 2024. "This is an exciting time for Novavax, and we have been keenly focused on evolving our operating model to leverage our key drivers of value," said John C. Jacobs, President and Chief Executive Officer, Novavax. "We intend to drive future value for the business through not only the Sanofi partnership, but also through our late-stage combination and influenza assets. We plan to unveil a new and expanded clinical pipeline by the end of this year and leverage both the pipeline and our proven technology to drive additional partnerships and deals and to ultimately drive significant, long-term value for our shareholders." Second Quarter 2024 and Recent Highlights During the second quarter, Novavax continued executing against its four key priorities for the remainder of 2024. Priority #1: Successful Execution of Sanofi Partnership Novavax has taken steps to enable a successful operationalization of the collaboration and license agreement (the Sanofi Agreement) with Sanofi Pasteur Inc. (Sanofi). Effective January 1, 2025, Sanofi will assume primary commercial responsibility for Novavax's updated 2024-2025 formula COVID-19 vaccine (NVX-CoV2705) in the U.S., Europe and select major markets not currently subject to Novavax Advance Purchase Agreements (APAs) or existing partnership agreements. Received $500 million upfront payment and an approximately $70 million equity investment from Sanofi. Novavax is eligible to receive up to $700 million in development, regulatory and launch milestones for activities related to commercializing Nuvaxovid™ and advancing Sanofi's flu-COVID-19 combination vaccine candidate plus royalties. In addition, Novavax is eligible to receive royalties associated with any other Nuvaxovid combination vaccine Sanofi chooses to develop. For each additional Sanofi vaccine product developed under the non-exclusive license with Novavax's Matrix-M adjuvant technology, Novavax is eligible to receive additional launch and sales milestones of up to $210 million per product plus ongoing product royalties. Priority #2: Drive Incremental Value from Novavax's Proven Technology Platform Novavax continued to leverage its technology platform to drive value creation. On track to initiate the Phase 3 immunogenicity trial for both COVID-19-Influenza Combination (CIC) and stand-alone influenza vaccine candidates in the fourth quarter of 2024, with data expected by mid-2025. Conducting pipeline prioritization activities to determine Novavax's lead portfolio programs. Priority #3: Continue Evolution of Novavax and Reduce Operating Expenses Novavax continued to progress its cost reduction program to create a more lean and agile organization and accelerate its focus on Research and Development (R&D). On track with global restructuring and cost reduction plan with an approximately 34% reduction in combined R&D and Selling, General and Administrative (SG&A) expenses in the second quarter of 2024 compared to the same period for 2023. Prepared to initiate an additional cost reduction program to reduce R&D plus SG&A expenses, with a portion of expenses to be reimbursed by Sanofi under the Sanofi Agreement. Novavax plans to continue assessing existing capabilities to further refine the shape, size and scope of its organization this year and into 2025. Targeting full year combined R&D and SG&A expenses to be below $500 million for full year 2025 and below $350 million for full year 2026. Novavax expects greater than $50 million of such expenses in 2025 to be reimbursed by Sanofi under the Sanofi Agreement, resulting in adjusted combined R&D and SG&A expenses, net of Sanofi reimbursement costs under the Sanofi Agreement, of below $450 million for full year 2025. Priority #4: Deliver an Updated COVID-19 Vaccine for the 2024-2025 Vaccination Season Novavax expects to deliver its updated 2024-2025 formula COVID-19 vaccine to the market by the start of the season. U.S. Market: Submitted an Emergency Use Authorization (EUA) amendment to the U.S. Food and Drug Administration (FDA). Advanced manufacturing of pre-filled syringe presentation of updated 2024-2025 formula COVID-19 vaccine following FDA strain selection guidance. Expect doses will be ready to ship upon receipt of EUA. FDA accepted the Biologics License Application (BLA) for Novavax's COVID-19 vaccine with a Prescription Drug User Fee Act date of April 2025. Advanced retail pharmacy contract negotiations to enhance access for the 2024-2025 vaccination season. Global Markets: For 2024, made decision to conduct lean and targeted commercial launch in Europe in select key countries including Germany, Italy and Poland. Submitted marketing authorization amendments to the European Medicines Agency (EMA) and expect doses will be ready to ship upon receipt of market authorization. Second Quarter 2024 Financial Results Total revenue for the second quarter of 2024 was $415 million, compared to $424 million in the same period in 2023. Second quarter 2024 licensing, royalties and other revenue includes $391 million associated with the $500 million upfront payment received under the Sanofi Agreement. Cost of sales for the second quarter of 2024 was $46 million, compared to $56 million in the same period in 2023. These quarters included $24 million and $31 million, respectively, related to excess, obsolete or expired inventory, losses on firm purchase commitments under third-party supply agreements and unutilized manufacturing capacity. R&D expenses for the second quarter of 2024 were $107 million, compared to $219 million in the same period in 2023. The decrease was primarily due to reductions in manufacturing and clinical research-related spend. SG &A expenses for the second quarter of 2024 were $101 million, compared to $94 million for the same period in 2023. The increase was primarily due to certain fees paid in association with signing the Sanofi Agreement. Net income for the second quarter 2024 was $162 million, compared to a net income of $58 million in the same period in 2023. Cash, cash equivalents, marketable securities and restricted cash (Cash) were $1.1 billion as of June 30, 2024, compared to $584 million as of December 31, 2023. Financial Framework Novavax is updating its Full Year 2024 Financial Guidance and expects to achieve the following objectives. Full Year 2024 Guidance Prior full year 2024 Total Revenue guidance includes product sales, royalties and other revenue and did not reflect revenue attributable to the initial payments received from Sanofi pursuant to the Sanofi Agreement in the second quarter of 2024. Prior full year 2024 Total Revenue guidance reflects APA expected dose delivery schedules of $150 million to $250 million and non-APA related revenue of $250 million to $350 million, subject to updated variant manufacturing and regulatory approvals, from a combination of commercial market product sales plus royalties and other revenue from partner-related activities. Initial Sanofi Agreement payments received in the second quarter of 2024 include a non-refundable $500 million upfront payment and a $69 million equity investment in Novavax. Full year 2024 product sales guidance reflects approximately $100 million in APA dose deliveries in 1H 2024 and $175 million to $275 million of commercial market sales expected in 2H 2024, subject to updated variant manufacturing and regulatory approvals. Full year 2024 guidance for Licensing, royalties and other revenue includes $400 million of revenue recognition from the $500 million Sanofi agreement upfront payment and $25 million in royalty and other revenue from partner-related activities. Combined R&D and SG&A expenses expected at the higher end of the range to account for the Sanofi Agreement transaction costs. Conference Call Novavax will host its quarterly conference call today at 8:30 a.m. ET. To join the call without operator assistance, you may register and enter your phone number at to receive an instant automated call back. You may also dial direct to be entered to the call by an operator. The dial-in numbers for the conference call are (800) 836-8184 (Domestic) or (+1) (646) 357-8785 (International). Participants will be prompted to request to join the Novavax, Inc. call. A replay of the conference call will be available starting at 11:30 a.m. ET on August 8, 2024, until 11:59 p.m. ET on August 15, 2024. To access the replay by telephone, dial (888) 660-6345 (Domestic) or (+1) (646) 517-4150 (International) and use passcode 414036 #. A webcast of the conference call can also be accessed on the Novavax website at ir.novavax.com/events. A replay of the webcast will be available on the Novavax website until September 8, 2024. Trade Name in the U.S. The trade name Nuvaxovid has not been approved by the U.S. FDA. About Novavax Novavax, Inc. (Nasdaq: NVAX) promotes improved health by discovering, developing and commercializing innovative vaccines to help protect against serious infectious diseases. Novavax, a global company based in Gaithersburg, Md., U.S., offers a differentiated vaccine platform that combines a recombinant protein approach, innovative nanoparticle technology and Novavax's patented Matrix-M adjuvant to enhance the immune response. The Company's portfolio includes its COVID-19 vaccine and its pipeline includes CIC and stand-alone influence vaccine candidates. In addition, Novavax's adjuvant is included in the University of Oxford and Serum Institute of India's R21/Matrix-M malaria vaccine. Please visit novavax.com and LinkedIn for more information. Non-GAAP Financial Measures The Company has used a non-GAAP financial measure in this press release, which is adjusted combined R&D and SG&A expenses, net of Sanofi reimbursement costs under the Sanofi Agreement. Non-GAAP financial measures refer to financial information adjusted from financial measures prepared in accordance with accounting principles generally accepted in the United States (GAAP). The Company believes that the presentation of this adjusted financial measure is useful to investors as it provides additional information on comparisons between periods by including certain items that affect overall comparability. The Company uses this non-GAAP financial measure for business planning purposes and to consider underlying trends of its business, and believes presenting this measure also provides useful information to investors and others for understanding and evaluating trends in the Company's expenses in the same manner as the Company's management. Non-GAAP financial measures should be considered in addition to, and not as an alternative for, the Company's reported results prepared in accordance with GAAP. The use of this non-GAAP financial measure may differ from similar measures reported by other companies and may not be comparable to other similarly titled measures. Forward-Looking Statements Statements herein relating to the future of Novavax, its mission, its near-term priorities including a successful transition under the Sanofi partnership, driving incremental value from Novavax's technology platform, delivering an updated 2024-2025 formula COVID-19 vaccine for the start of the 2024-2025 vaccination season in a pre-filled syringe presentation, launching a Phase 3 trial for CIC and stand-alone influenza in the fourth quarter of 2024, with data expected by mid-2025, and reducing operations expenses, including by initiating an additional cost reduction program, the anticipated timing of potential BLA approval for Novavax's prototype COVID-19 vaccine and XBB COVID-19 vaccine and EUA for Novavax's updated 2024-2025 formula COVID-19 vaccine, potential royalties and milestones under the agreement with Sanofi, its operating plans, objectives and prospects, updated full year 2024 financial guidance, its commercial launch plans for the 2024-2025 vaccination season, its future financial or business performance, conditions or strategies, and the downsizing of commercial operations in Europe are forward-looking statements. Novavax cautions that these forward-looking statements are subject to numerous risks and uncertainties that could cause actual results to differ materially from those expressed or implied by such statements. These risks and uncertainties include, without limitation, Novavax's and Sanofi's ability to successfully implement its partnership, including the ability to transition key processes and effect technology transfers, Novavax's ability to successfully and timely manufacture, distribute, or market its updated 2024-2025 formula COVID-19 vaccine including as a single dose vial or pre-filled syringe product presentation for the 2024-2025 vaccination season and its ability to receive a BLA from the FDA for the 2024-2025 vaccination season; challenges related to Novavax's new partnership with Sanofi; challenges satisfying, alone or together with partners, various safety, efficacy, and product characterization requirements, including those related to process qualification, assay validation and stability testing, necessary to satisfy applicable regulatory authorities; challenges or delays in conducting clinical trials; challenges or delays in obtaining regulatory authorization for its product candidates, including its updated COVID-19 vaccine in time for the 2024-2025 vaccination season or for future COVID-19 variant strain changes, its CIC and stand-alone influenza vaccine candidate; manufacturing, distribution or export delays or challenges; Novavax's substantial dependence on Serum Institute of India Pvt. Ltd. and Serum Life Sciences Limited for co-formulation and filling and PCI Pharma Services for finishing Novavax's COVID-19 vaccine and the impact of any delays or disruptions in their operations on the delivery of customer orders; difficulty obtaining scarce raw materials and supplies, including for its proprietary adjuvant; resource constraints, including human capital and manufacturing capacity, constraints on Novavax's ability to pursue planned regulatory pathways, alone or with partners, in multiple jurisdictions simultaneously, leading to staggering of regulatory filings, and potential regulatory actions; challenges in implementing its global restructuring and cost reduction plan and additional cost reduction program; Novavax's ability to timely deliver doses; challenges in obtaining commercial adoption and market acceptance of its updated 2024-2025 formula COVID-19 vaccine or any COVID-19 variant strain containing formulation; challenges meeting contractual requirements under agreements with multiple commercial, governmental, and other entities, including requirements to deliver doses that may require Novavax to refund portions of upfront and other payments previously received or result in reduced future payments pursuant to such agreements and challenges in amending or terminating such agreements; challenges related to the seasonality of vaccinations against COVID-19; challenges related to the demand for vaccinations against COVID-19; and those other risk factors identified in the "Risk Factors" and "Management's Discussion and Analysis of Financial Condition and Results of Operations" sections of Novavax's Annual Report on Form 10-K for the year ended December 31, 2023, and subsequent Quarterly Reports on Form 10-Q, as filed with the Securities and Exchange Commission (SEC). We caution investors not to place considerable reliance on forward-looking statements contained in this press release. You are encouraged to read our filings with the SEC, available at and , for a discussion of these and other risks and uncertainties. The forward-looking statements in this press release speak only as of the date of this document, and we undertake no obligation to update or revise any of the statements. Our business is subject to substantial risks and uncertainties, including those referenced above. Investors, potential investors, and others should give careful consideration to these risks and uncertainties. Contacts: Investors Erika Schultz 240-268-2022 [email protected] Media Giovanna Chandler 202-709-5563 [email protected] SOURCE Novavax, Inc.

On a day when struggling Novavax slashed its 2024 revenue projection from a range of $800 million to $1 million to a window of $400 million to $600 million, the company announced that it has partnered with vaccine powerhouse Sanofi in a $1.2 billion deal. After years of missteps in developing and commercializing its coronavirus shot, Novavax is turning to one of the biopharma industry’s most experienced vaccine companies to help salvage its COVID efforts: Sanofi. The French Big Pharma will partner with the struggling Maryland biotech to co-commercialize its COVID-19 jab Nuvaxovid and develop combination vaccines. In all, Novavax will receive $500 million up front, plus up to $700 million in potential development, regulatory and launch milestones plus tiered royalties. As part of the arrangement, Sanofi is taking a 4.9% equity position in Novavax. Sanofi will book sales for Nuvaxovid at the start of next year. The French company’s vaccine legacy includes developing, manufacturing and commercializing shots worldwide to protect against polio, rabies, meningitis and the flu. The partnership allows Novavax to lift its “going concern” notice from February when it warned investors that the plunging demand for COVID vaccines could send the company into bankruptcy. It also relieves Novavax from pressure from activist investor Shah Capital, which called the company “historically mismanaged,” in a public letter last month. With the announcement, Novavax’s share price increased by 121% to $9.89—still far from the $289 price Novavax’s shares attracted in February 2021 when the company was hailed as a rags-to-riches story after scoring a $1.6 billion government grant to develop its COVID shot. During a Friday conference call, Novavax CEO John Jacobs called the deal “the beginning of a new chapter for the future of our company.” “I’d rather not comment on what Sanofi may be thinking or why they came to the conclusion why this is such an exciting platform to partner with, but we’re not surprised because we know the value our technology can offer,” Jacobs added. The agreement gives more people around the world access to Nuvaxovid, a traditional, protein-based adjuvanted vaccine, which differs from the mRNA-type shots manufactured by Moderna and Pfizer and its German partner BioNTech. In exchange, Sanofi receives access to Novavax’s Matrix-M adjuvant technology. Novavax can receive up to $200 million plus tiered royalties for each Sanofi vaccine product developed using the platform. Novavax will retain the rights to a combination COVID/flu vaccine that's under development, while Sanofi gains the ability to use Nuvaxovid in developing non-influenza combination vaccines. “We have an opportunity to develop non-mRNA flu-COVID-19 combination vaccines, offering patients both enhanced convenience and protection against two serious respiratory viruses,” Jean-Francois Toussaint, Sanofi’s head of vaccines R&D, said in a release. “We're excited by the prospect of combining Novavax's adjuvanted COVID-19 vaccine that has shown high efficacy and favorable tolerability with our rich portfolio of differentiated flu vaccines.” Novavax’s urgency to make a deal was highlighted on Friday as the company presented its quarterly financial report, slashing its guidance for annual sales from a range of $800 million to $1 billion to a window of $400 million to $600 million. The company achieved revenue of $2 billion in 2022 and $984 million in 2023. This comes as AstraZeneca is pulling its non-mRNA COVID vaccine from markets around the world. This week the EMA said it had accepted a request from AZ and withdrawn the company’s European marketing authorization for its pandemic shot Vaxzevria. “As multiple, variant COVID-19 vaccines have since been developed there is a surplus of available updated vaccines,” the company said. “This has led to a decline in demand for Vaxzervria, which is no longer being manufactured or supplied.”